黄素对通过AKAP150/PKA/PP2B复合体诱导的desipramine诱导的岛屿β细胞损伤的保护作用
Min Hu1, Jia-Ying Cai1,2, Yao He1
1Department of Pharmacology, School of Basic Medical Sciences, Peking University & Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing, 100191, China.
Acta pharmacologica Sinica
|October 16, 2023
概括
黄素通过调节关键分子通路,保护胰腺β细胞免受抗抑郁药诱导的亡. 这种天然化合物在与抗抑郁药一起使用时可能提供治疗益处,特别是对于糖尿病患者.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 三环抗抑郁药 (TCA) 可以提高血糖,抑制胰岛素分泌,对糖尿病患者构成风险.
- 黄是一种来自黄的化合物,具有抗抑郁和抗糖尿病的特性.
- 这项研究研究了黄素对抗德西普拉胺诱导的β细胞亡的保护作用.
研究的目的:
- 评估黄素对胰腺β细胞的保护作用,以防止desipramine诱导的亡.
- 阐明库尔库的保护作用背后的分子机制.
- 评估黄素作为抗抑郁药治疗的辅助疗法的潜力.
主要方法:
- 鼠标强迫游泳试验 (FST) 来评估抗抑郁药物的活性.
- 在体内评估胰岛素分泌和血糖水平.
- 使用RIN-m5F胰腺β细胞进行体外研究,以评估细胞活力和亡.
- 对酶-3激活,线粒体膜潜力,活性氧物种 (ROS) 生成和蛋白质转位 (FOXO1,AKAP150/PP2B) 的分析.
主要成果:
- 结合黄素和desipramine治疗减少了FST的不运动时间,并使葡萄糖/胰岛素水平正常化.
- 库尔库防止了desipramine诱导的β细胞活力和胰岛素释放的减少.
- 库尔库通过增加Bcl-2/Bax比率,减少ROS,并阻断FOXO1核转位和AKAP150/PP2B相互作用来抑制desipramine诱导的亡.
结论:
- 黄素通过PI3K/AKT/FOXO1和AKAP150/PKA/PP2B通路保护胰腺β细胞免受脱胺诱导的亡.
- 黄素作为抗抑郁药物治疗的辅助药物具有治疗潜力,特别是用于控制代谢副作用.
相关概念视频
GPCR Desensitization
6.1K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.1K
Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192
Desensitization and Tachyphylaxis
1.8K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.8K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334


